Share
))
HBO and The Ringer's Bill Simmons hosts the most downloaded sports podcast of all time, with a rotating crew of celebrities, athletes, and media staples, as well as mainstays like Cousin Sal, Joe House, and a slew of other friends and family members who always happen to be suspiciously available.
…
continue reading
Manage episode 516137335 series 3698063
Content provided by Niraj Sharma and Niraj Sharma MD FACC FHRS. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Niraj Sharma and Niraj Sharma MD FACC FHRS or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
What if stroke prevention in atrial fibrillation no longer meant trading protection for bleeding risk?
Factor XI inhibition—led by trials like AZALEA–TIMI 71, LILAC–TIMI 76, and LIBREXIA–AF—is poised to rewrite the anticoagulation playbook. By targeting the intrinsic pathway, these agents may decouple thromboembolic protection from major bleeding, potentially reshaping the role of left atrial appendage occlusion (LAAO) in stroke prevention strategies.
In this episode of EP Edge, Dr. Niraj Sharma breaks down the evolving data, drug classes, mechanistic rationale, and implications for future guidelines—while also looking at where structural interventions may still fit in this shifting landscape.
For: Source data/infographics see EPEDGE Newsletter on LinkedIn
For feedback, collaborations, or questions, email Dr. Niraj Sharma at [email protected] or connect on LinkedIn
7 episodes
